A Lingering Disquiet: Bausch Health

The setback regarding Xifaxan, their flagship product, is less a catastrophe than a gentle reminder of the impermanence of things. The inevitable arrival of generic competitors was known, of course. The attempt to prolong its reign through expanded labeling—treating cirrhosis, no less—was, perhaps, a touch optimistic. The clinical trial’s failure? A minor disappointment, easily absorbed into the general atmosphere of…acceptance.








